Combination Gefitinib and Methotrexate for the Treatment of Persistent Gestational Trophoblastic Disease: A Phase I Clinical Trial

Phase 1

• Conditions: Persistent Gestational Trophoblastic Disease; Reproductive Health and Childbirth - Other reproductive health and childbirth disorders; Cancer - Other cancer types

• Registration Number: ACTRN12611000104954
• Lead Sponsor: Miss Orla McNally, Director Gynaecological Oncology & Dysplasia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-01-31
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: Female
• Target Recruitment: 12

Inclusion Criteria

Persistent gestational trophoblastic disease diagnosed on tissue histopathology and confirmed by persistence of serum beta human chorionic gonadotropin levels.

Exclusion Criteria

Chronic pulmonary disease (excluding mild asthma), severe gastrointesitinal or dermatological disease, Japanese ethinicity, allergy to methotrexate or gefitinib.

Study & Design

• Study Type: Interventional
• Study Design: Not specified